Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Total Current Liabilities (2016 - 2025)

Arcadia Biosciences' Total Current Liabilities history spans 12 years, with the latest figure at $2.1 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities fell 19.66% year-over-year to $2.1 million; the TTM value through Dec 2025 reached $2.1 million, down 19.66%, while the annual FY2025 figure was $2.1 million, 19.66% down from the prior year.
  • Total Current Liabilities reached $2.1 million in Q4 2025 per RKDA's latest filing, down from $2.3 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $7.7 million in Q2 2021 to a low of $1.8 million in Q2 2025.
  • Average Total Current Liabilities over 5 years is $3.9 million, with a median of $4.0 million recorded in 2022.
  • Peak YoY movement for Total Current Liabilities: tumbled 40.08% in 2024, then dropped 1.85% in 2025.
  • A 5-year view of Total Current Liabilities shows it stood at $5.0 million in 2021, then fell by 16.49% to $4.2 million in 2022, then dropped by 14.71% to $3.6 million in 2023, then dropped by 28.61% to $2.6 million in 2024, then fell by 19.66% to $2.1 million in 2025.
  • Per Business Quant, the three most recent readings for RKDA's Total Current Liabilities are $2.1 million (Q4 2025), $2.3 million (Q3 2025), and $1.8 million (Q2 2025).